Andrea Muranyi
Overview
Explore the profile of Andrea Muranyi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
561
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Williams C, Gray R, Hills R, Shires M, Zhang L, Zhao Z, et al.
J Clin Oncol
. 2024 Jul;
42(29):3430-3442.
PMID: 39083705
Purpose: High densities of tumor infiltrating CD3 and CD8 T-cells are associated with superior prognosis in colorectal cancer (CRC). Their value as predictors of benefit from adjuvant chemotherapy is uncertain....
2.
Halldorsson S, Hillringhaus L, Hojer C, Muranyi A, Schraeml M, Lange M, et al.
Sci Rep
. 2024 Jul;
14(1):16512.
PMID: 39020051
Prostate-specific antigen (PSA) levels are widely used to screen for prostate cancer, yet the test has poor sensitivity, specificity and predictive value, which leads to overdiagnosis and overtreatment. Alterations in...
3.
Saberzadeh-Ardestani B, Graham R, McMahon S, Ahanonu E, Shi Q, Williams C, et al.
Clin Cancer Res
. 2023 Aug;
29(20):4268-4277.
PMID: 37566222
Purpose: Targeting the programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) interaction has led to durable responses in fewer than half of patients with mismatch repair-deficient (MMR-d)...
4.
Williams C, Elliott F, Sapanara N, Aghaei F, Zhang L, Muranyi A, et al.
Clin Cancer Res
. 2023 Jun;
29(20):4153-4165.
PMID: 37363997
Purpose: High tumor production of the EGFR ligands, amphiregulin (AREG) and epiregulin (EREG), predicted benefit from anti-EGFR therapy for metastatic colorectal cancer (mCRC) in a retrospective analysis of clinical trial...
5.
Chakrabarti S, Huebner L, Finnes H, Muranyi A, Clements J, Singh S, et al.
JCO Precis Oncol
. 2022 Feb;
3:1-7.
PMID: 35100708
No abstract available.
6.
Raghav K, Loree J, Morris J, Overman M, Yu R, Meric-Bernstam F, et al.
JCO Precis Oncol
. 2022 Feb;
3:1-13.
PMID: 35100667
Purpose: amplification has been implicated in resistance to therapy with anti-epidermal growth factor receptor antibodies (anti-EGFRabs) in metastatic colorectal cancer (mCRC). The purpose of the study was to validate the...
7.
Jary M, Liu W, Yan D, Bai I, Muranyi A, Colle E, et al.
Mol Oncol
. 2021 Dec;
16(11):2260-2273.
PMID: 34954864
In the era of immune checkpoint inhibitors, understanding the metastatic microenvironment of proficient mismatch repair/microsatellite stable (pMMR/MSS) colorectal cancer (CRC) is of paramount importance to both prognostication and the development...
8.
Rounds L, Nagle R, Muranyi A, Jandova J, Gill S, Vela E, et al.
Cancers (Basel)
. 2021 Jul;
13(14).
PMID: 34298821
Glyoxalase 1 (GLO1) is an enzyme involved in the detoxification of methylglyoxal (MG), a reactive oncometabolite formed in the context of energy metabolism as a result of high glycolytic flux....
9.
Salles D, Vidotto T, Faisal F, Tosoian J, Guedes L, Muranyi A, et al.
J Mol Diagn
. 2021 Jun;
23(8):1030-1041.
PMID: 34062284
This study leveraged a gene-protein assay to assess MYC and PTEN status at prostate cancer biopsy and examined the association with adverse outcomes after surgery. MYC gain and PTEN loss...
10.
Williams C, Seligmann J, Elliott F, Shires M, Richman S, Brown S, et al.
Clin Cancer Res
. 2021 Apr;
27(12):3422-3431.
PMID: 33888518
Purpose: High tumor mRNA levels of the EGFR ligands amphiregulin (AREG) and epiregulin (EREG) are associated with anti-EGFR agent response in metastatic colorectal cancer (mCRC). However, ligand RNA assays have...